Eli Lilly has agreed to acquire axonal degeneration specialist Disarm Therapeutics in exchange for US$135 M upfront. Disarm develops disease-modifying therapies that target the SARM1 protein, which has been identified by Disarm’s scientific founders as the central driver of axonal degeneration. Lilly intends to develop Disarm’s SARM1 inhibitors in peripheral neuropathy and neurological diseases, such as ALS and multiple sclerosis - indications for which Lilly lacks assets in clinical development.